From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Estimating the value of net sales adjustments from a Finance perspective can be very difficult due to a lack of available internal data and market information. The problem is especially acute before launch and in the first few quarters the product is on the market.
IntegriChain often provides market-level benchmarks and analogs (i.e., metadata) that can serve as the foundation of a data-driven approach to financial planning & analysis for product launch. Manufacturers adopting this methodology would then have a credible source as the basis for estimating sales adjustments and a methodology that’s been readily accepted by external audit firms.
This white paper examines the use of Market Benchmark data to forecast:
